Overview

BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs

Status:
Withdrawn
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Phase II study designed to evaluate the safety and efficacy of BIIB057 in Subjects with Rheumatoid Arthritis who have experienced an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs).
Phase:
Phase 2
Details
Lead Sponsor:
Biogen
Treatments:
Antirheumatic Agents